Actively Recruiting
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-06-17
9999
Participants Needed
1
Research Sites
3704 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China. 1. Analyze the demographic and clinical characteristics of patients with LGLL, including sex, age, disease severity, and other relevant factors. 2. Examine disease features of LGLL patients, such as biochemical and hematological indicators, LGL counts, clonality, bone marrow pathology, and cytogenetics 3. Assess treatment patterns and real-world effectiveness in LGLL patients. 4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.
CONDITIONS
Official Title
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with large granular lymphocytic leukemia (LGLL)
- Treated at the Institute of Hematology and Blood Diseases Hospital from January 1, 2000
You will not qualify if you...
- Unlikely to be available for long-term follow-up due to inability to obtain follow-up data or severe other illnesses
- Alcohol or drug dependence that could reduce compliance with the study
- Any other reason the investigator considers makes the participant unsuitable for this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Red Blood Cell Diseases Center and Regenerative Medicine Center
Tianjin, Tianjin Municipality, China, 301617
Actively Recruiting
Research Team
L
Lele Zhang, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here